Groundbreaking cell therapy research
Research in the Davila Lab is dedicated to developing gene-engineered cell therapies that target cancer cells in preclinical models. The goal of our research is to identify optimal cell therapies that can then be evaluated in cancer patients.
Meet the PI
Innovations in CAR T-cell therapy
Working as a research fellow under Renier Brentjens, MD, PhD, Dr. Davila pioneered some of the first chimeric antigen receptor (CAR) T-cell therapies for patients with blood cancers. Their work led to a groundbreaking trial for patients with B-cell acute lymphoblastic leukemia (ALL) and discoveries that paved the way for the first FDA approvals for CAR T-cell therapies for cancer in 2017.
Now, the Davila Lab is working to unlock the next cell therapy breakthrough: Understanding how CAR T cells work or don’t work in patients and applying that new knowledge to develop treatment options for solid tumors.
Innovation in the lab and at the bedside
Join our team!
The Davila Lab is always looking for the best and brightest postdoctoral fellows and predoctoral trainees. If you have skills in immunology, biochemistry, metabolism, and cancer biology, email Dr. Buxbaum today to learn more!
Currently recuriting: Cancer Immunology Postdoc
Faculty affiliations
In the news
Connect with the Davila Lab
Email Dr. DavilaConnect on LinkedIn
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263